Potential Role of Anti-Complement Agents in the Treatment of COVID-19-Related ARDS.
作者信息
Spanopoulou Christina, Kassimos Dimitrios, Cassimos Dimitrios
机构信息
Department of Internal Medicine, General Hospital of Amaliada, Amaliada, Greece.
Paediatric Department, Democritus University of Thrace, Alexandroupolis, Greece.
出版信息
Mediterr J Rheumatol. 2020 Sep 8;31(Suppl 2):304-305. doi: 10.31138/mjr.31.3.304. eCollection 2020 Sep.
Abstract
摘要
相似文献
1
Potential Role of Anti-Complement Agents in the Treatment of COVID-19-Related ARDS.
Mediterr J Rheumatol. 2020 Sep 8;31(Suppl 2):304-305. doi: 10.31138/mjr.31.3.304. eCollection 2020 Sep.
2
Activation of the complement system in the adult respiratory distress syndrome.
Am Rev Respir Dis. 1987 Mar;135(3):651-8. doi: 10.1164/arrd.1987.135.3.651.
3
4
Experimental design of complement component 5a-induced acute lung injury (C5a-ALI): a role of CC-chemokine receptor type 5 during immune activation by anaphylatoxin.
FASEB J. 2015 Sep;29(9):3762-72. doi: 10.1096/fj.15-271635. Epub 2015 May 21.
5
Increased concentration of the complement split product C5a in acute pyelonephritis during pregnancy.
J Matern Fetal Neonatal Med. 2005 Apr;17(4):247-52. doi: 10.1080/14767050500072805.
6
Prostaglandin and complement interaction in clinical acute respiratory failure.
Arch Surg. 1986 Mar;121(3):271-4. doi: 10.1001/archsurg.1986.01400030025002.
7
Biochemical pathways of acute lung injury.
Bull Eur Physiopathol Respir. 1985 May-Jun;21(3):221-9.
8
Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates.
J Clin Invest. 1986 Jun;77(6):1812-6. doi: 10.1172/JCI112506.
9
10
How COVID-19 induces cytokine storm with high mortality.
Inflamm Regen. 2020 Oct 1;40:37. doi: 10.1186/s41232-020-00146-3. eCollection 2020.
引用本文的文献
1
Paroxysmal nocturnal hemoglobinuria in a patient post COVID-19 virus infection: A case report with literature review.
Clin Case Rep. 2023 Oct 9;11(10):e8011. doi: 10.1002/ccr3.8011. eCollection 2023 Oct.
2
COVID-19: General Strategies for Herbal Therapies.
J Evid Based Integr Med. 2022 Jan-Dec;27:2515690X211053641. doi: 10.1177/2515690X211053641.
本文引用的文献
1
Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed.
Lancet. 2020 May 2;395(10234):1407-1409. doi: 10.1016/S0140-6736(20)30858-8. Epub 2020 Apr 9.
2
COVID-19: consider cytokine storm syndromes and immunosuppression.
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
3
Acute Respiratory Distress Syndrome: An Update and Review.
J Transl Int Med. 2018 Jun 26;6(2):74-77. doi: 10.1515/jtim-2016-0012. eCollection 2018 Jun.
4
Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV.
Emerg Microbes Infect. 2018 Apr 24;7(1):77. doi: 10.1038/s41426-018-0063-8.
5
Pulmonary Involvement in Patients With Hemophagocytic Lymphohistiocytosis.
Chest. 2016 May;149(5):1294-301. doi: 10.1016/j.chest.2015.11.004. Epub 2016 Jan 13.
6
The role of C5a in acute lung injury induced by highly pathogenic viral infections.
Emerg Microbes Infect. 2015 May;4(5):e28. doi: 10.1038/emi.2015.28. Epub 2015 May 6.
7
Treatment with anti-C5a antibody improves the outcome of H7N9 virus infection in African green monkeys.
Clin Infect Dis. 2015 Feb 15;60(4):586-95. doi: 10.1093/cid/ciu887. Epub 2014 Nov 27.
8
Complement C5 activation during influenza A infection in mice contributes to neutrophil recruitment and lung injury.
PLoS One. 2013 May 16;8(5):e64443. doi: 10.1371/journal.pone.0064443. Print 2013.
9
Role of C3, C5 and anaphylatoxin receptors in acute lung injury and in sepsis.
Adv Exp Med Biol. 2012;946:147-59. doi: 10.1007/978-1-4614-0106-3_9.
10
Complement deficiency states and associated infections.
Mol Immunol. 2011 Aug;48(14):1643-55. doi: 10.1016/j.molimm.2011.05.001. Epub 2011 May 31.
Zotero 插件